Latest news

Förändring av antal aktier i Nanologica AB (publ)

31 October, 2022

Antalet aktier och röster i Nanologica AB har ändrats under oktober månad till följd av genomförandet av den tidigare kommunicerade företrädesemissionen. Som tidigare kommunicerats beslutade Nanologicas styrelse den 23 augusti 2022 om en nyemission om cirka 94 MSEK med företrädesrätt för befintliga aktieägare i syfte att finansiera intensifierade satsningar inom preparativ kromatografi. Den 10 oktober meddelade Nanologica att företrädesemissionen tecknats till 85 procent och att Nanologica genom företrädesemissionen tillförts cirka 79,8 MSEK, före emissionskostnader. Företrädesemissionen

5 Quick Questions with Katarina Alenäs

27 October, 2022

Katarina Alenäs, SVP Chromatography Nanologica AB Who is Katarina Alenäs? I have a M.Sc. in Chemical Engineering and a B.Sc. in Pharmaceutical Sciences and have spent most of my professional career within chromatography which is an area very close to my heart. Before joining Nanologica, I was the Country General Manager at Agilent Technologies Sweden, and before that I have been Product Manager Shimadzu HPLC/LCMS and I started my career as a Development Engineer of

Nanologica Announces Nomination Committee for the Annual General Meeting 2023

20 October, 2022

In accordance with the resolution at the Annual General Meeting (“AGM”) on June 2, 2022, the chairman of the board has contacted the company’s three largest owners or ownership groups in terms of votes as of September 30, 2022, each of whom has appointed a representative to constitute the nomination committee of Nanologica AB for the 2023 AGM. The nomination committee for Nanologica AB’s 2023 AGM thus consists of the following three members: Carl-Johan Spak

Nanologicas valberedning utsedd inför årsstämman 2023

20 October, 2022

I enlighet med beslut på årsstämman den 2 juni 2022 har styrelsens ordförande kontaktat bolagets tre röstmässigt största ägare eller ägargrupper per den 30 september 2022, som var och en har utsett en representant att utgöra valberedning i Nanologica AB inför årsstämman 2023. Valberedningen inför Nanologica AB:s årsstämma 2023 utgörs därmed av följande tre ledamöter: Carl-Johan Spak (Flerie Invest AB) Lennart Francke (Swedbank Robur Microcap) Joakim Persson (Vega Bianca AB) Valberedningen representerar tillsammans 47,9 procent

MVIC Inhalation Symposium

11 October, 2022

October 12-13, Nanologica will take part of the MVIC Inhalation Symposium in Lund where Nanologica’s Senior Scientist Dr Georgia Pilkington will give a speach on Evaluation of Nanoporous Particles as a Delivery Vehicle for Inhaled Drugs. MVIC Symposium in Lund 12-13 October 2022

Nanologica Raises MSEK 79,8 in Rights Issue

10 October, 2022

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Nanologica AB (publ) (”Nanologica” or the “Company”) today announces the outcome of the new shares issue with preferential rights for Nanologica’s existing shareholders (the

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.

Categories

News archive